Recreating a woolly mammoth calf by 2028 is the extraordinary promise US-based genetic engineering company Colossal Biosciences ... logo. The duo, named Chip and Dale, have “high precision ...

CME Group, the world's leading derivatives marketplace, today announced the first day of trading in High Yield Duration-Hedged Credit futures, its fourth contract based on Bloomberg corporate bond ...

Precision BioSciences (DTIL) announced the presentation of preclinical data for its PBGENE-DMD development program for the treatment of ...

Analysts have set 12-month price targets for Precision BioSciences, revealing an average target of $53.5, a high estimate of $60.00, and a low estimate of $34.00. Staying constant with the previous ...

Precision BioSciences (DTIL) announced that the U.S. Food and Drug Administration or FDA has cleared the Investigational New Drug application ...

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing ...

The abstract is now publicly accessible through the MDA website here. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving ...

Precision Biosciences' ARCUS platform offers high precision and versatility, supporting in vivo gene editing therapies, and has secured strategic partnerships for azer-cel's development in cancer ...

Precision BioSciences (NASDAQ:DTIL – Get Free Report)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research report issued on Wednesday,Benzinga reports. They currently ...

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, including gene ...